MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

Food and Healthcare Press Releases Tuesday January 8, 2019 08:20
SAN JOSE, Calif.--8 Jan--PRNewswire/InfoQuest

MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's early access program for its newest ultra-high-throughput genetic sequencer, MGISEQ-T7, during a presentation at China Focus@JPM Week on the eve of the 37th annual J.P. Morgan Healthcare Conference.

The MGISEQ-T7 vastly improves speed, throughput and flexibility of DNA sequencing by enabling simultaneous but independent operation of up to four flow cells in a single run. The innovative quad-flowcell platform allows multiple flow cells with different read lengths and applications to be processed separately at any time. Sequencing of PE150 takes less than 24 hours at full load to complete. The MGI proprietary technologies, including DNBseq(TM) used in T7, deliver exceptionally high accuracy and improve efficiency through upgrades to the flowcell, fluidics, and biochemical and optical system. The platform can produce up to 6Tb of daily data, equivalent to up to 60 whole human genomes in a single day.

MGI's technology improves the speed, efficiency and affordability of large population health projects. In the past, a 100,000-population-genome program would take four to six years to complete, but now using six MGISEQ-T7 sequencers such projects could be completed in just one year, at much lower cost.

The early access program supports collaboration on the development of genetic technologies and applications. It allows customization of instruments and reagents and innovative financial models. MGI is planning to expand this program internationally over the coming year. The MGI platform is gaining support around the world, with more than 135 publications using MGI sequencers and over 20 petabytes of data generated.

Besides its sequencer product portfolio, MGI has developed a product portfolio of automated sample preparation workstations to meet the needs of ultra-high-throughput genomic sequencing. Dr. Jiang also introduced the MGISP workstations series of products for sample preparation, MegaBOLT series of products for accelerating bioinformatics analysis, and ZLIMS software system for lab management with NGS sequencing process.

At the J.P. Morgan Healthcare Conference, MGI also announced a global partnership with Paragon Genomics, a leader in amplicon-based target enrichment and library preparation solutions for next-generation sequencing (NGS) assays. MGI will distribute Paragon Genomics' CleanPlex(R)NGS Panels for use with MGI's sequencing platforms in all territories worldwide except the U.S., and Paragon Genomics will distribute MGI's automated sample preparation workstation systems in the U.S. and Canada.

About MGI

MGI Tech Co., Ltd. (MGI), a subsidiary of BGI Group, is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare. MGI's multi-omics platforms include genetic sequencing, mass spectrometry and medical imaging. Providing real-time, comprehensive, life-long solutions, its mission is to develop and promote advanced life science tools for future healthcare.

About BGI Group

BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated more than 2,130 publications. BGI's goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry's broadest array of leading technologies, including BGI's own sequencing platform, economies of scale, and expert bioinformatics resources. BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare.

Kristi Heim, BGI Deputy Director of Communications
+1 206-778-7411
Photo -
Caption - MGI's COO Dr. Jiang Hui at the 37th annual J.P. Morgan Healthcare
Photo -
Caption - Ultra-high-throughput Genetic Sequencer MGISEQ-T7
Photo -
Caption - Proprietary Sequencing Technology MGISEQ/BGISEQ's Progress
Photo -
Caption - MGISEQ-2000 Genetic Sequencer

Latest Press Release

Osotspa joins with Banphaeo Hospital to provide free surgeries to give sight back to patients with cataracts

Osotspa Public Company Limited has joined together with Banphaeo Hospital to give senior citizens and the underprivileged in remote areas who needed cataract surgery their sight back so they can resume living normal lives, an initiative that reflects the...

Financial year 2018: Boehringer Ingelheim grows and invests

- Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseases - Operating growth outpaces the market in all businesses - Technical integration of the animal health business acquired in 2017 successfully completed The...

#RosaceaNoFilter: Online Influencers Take the Lead in Raising Rosacea Awareness in Galderma#s Empowering Rosacea Awareness Month Social Media Campaign

As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share...

Galderma Marks Rosacea Awareness Month With New Insights Into Why Some Patients Are Self-treating and Launches Social Media Campaign to Reinforce Hidden Impact of the Disease

Galderma extends its commitment to understanding the beyond the visible impact of rosacea with new patient insights supporting healthcare professionals' understanding of patient behavior and revealing possible motivations for not reconsulting Building...

Sun Life Financial Asia Releases New Diabetes in Asia Report

More than 60% of diabetics live in Asia; Community-based approach needed to create opportunities for change A coordinated, community-based approach is essential to hold back the rising tide of diabetes in Asia, according to a new report from Sun Life...

Related Topics